BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 29345617)

  • 1. Loss of functional BAP1 augments sensitivity to TRAIL in cancer cells.
    Kolluri KK; Alifrangis C; Kumar N; Ishii Y; Price S; Michaut M; Williams S; Barthorpe S; Lightfoot H; Busacca S; Sharkey A; Yuan Z; Sage EK; Vallath S; Le Quesne J; Tice DA; Alrifai D; von Karstedt S; Montinaro A; Guppy N; Waller DA; Nakas A; Good R; Holmes A; Walczak H; Fennell DA; Garnett M; Iorio F; Wessels L; McDermott U; Janes SM
    Elife; 2018 Jan; 7():. PubMed ID: 29345617
    [TBL] [Abstract][Full Text] [Related]  

  • 2. BAP1 and YY1 regulate expression of death receptors in malignant pleural mesothelioma.
    Ishii Y; Kolluri KK; Pennycuick A; Zhang X; Nigro E; Alrifai D; Borg E; Falzon M; Shah K; Kumar N; Janes SM
    J Biol Chem; 2021 Nov; 297(5):101223. PubMed ID: 34597666
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The BAP1/ASXL2 Histone H2A Deubiquitinase Complex Regulates Cell Proliferation and Is Disrupted in Cancer.
    Daou S; Hammond-Martel I; Mashtalir N; Barbour H; Gagnon J; Iannantuono NV; Nkwe NS; Motorina A; Pak H; Yu H; Wurtele H; Milot E; Mallette FA; Carbone M; Affar el B
    J Biol Chem; 2015 Nov; 290(48):28643-63. PubMed ID: 26416890
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Loss of BAP1 function leads to EZH2-dependent transformation.
    LaFave LM; Béguelin W; Koche R; Teater M; Spitzer B; Chramiec A; Papalexi E; Keller MD; Hricik T; Konstantinoff K; Micol JB; Durham B; Knutson SK; Campbell JE; Blum G; Shi X; Doud EH; Krivtsov AV; Chung YR; Khodos I; de Stanchina E; Ouerfelli O; Adusumilli PS; Thomas PM; Kelleher NL; Luo M; Keilhack H; Abdel-Wahab O; Melnick A; Armstrong SA; Levine RL
    Nat Med; 2015 Nov; 21(11):1344-9. PubMed ID: 26437366
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Genetic screens reveal new targetable vulnerabilities in BAP1-deficient mesothelioma.
    Pandey GK; Landman N; Neikes HK; Hulsman D; Lieftink C; Beijersbergen R; Kolluri KK; Janes SM; Vermeulen M; Badhai J; van Lohuizen M
    Cell Rep Med; 2023 Feb; 4(2):100915. PubMed ID: 36657447
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Structural basis of histone H2A lysine 119 deubiquitination by Polycomb repressive deubiquitinase BAP1/ASXL1.
    Thomas JF; Valencia-Sánchez MI; Tamburri S; Gloor SL; Rustichelli S; Godínez-López V; De Ioannes P; Lee R; Abini-Agbomson S; Gretarsson K; Burg JM; Hickman AR; Sun L; Gopinath S; Taylor HF; Sun ZW; Ezell RJ; Vaidya A; Meiners MJ; Cheek MA; Rice WJ; Svetlov V; Nudler E; Lu C; Keogh MC; Pasini D; Armache KJ
    Sci Adv; 2023 Aug; 9(32):eadg9832. PubMed ID: 37556531
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inactivation of
    Kukuyan AM; Sementino E; Kadariya Y; Menges CW; Cheung M; Tan Y; Cai KQ; Slifker MJ; Peri S; Klein-Szanto AJ; Rauscher FJ; Testa JR
    Cancer Res; 2019 Aug; 79(16):4113-4123. PubMed ID: 31151962
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Loss of the deubiquitylase BAP1 alters class I histone deacetylase expression and sensitivity of mesothelioma cells to HDAC inhibitors.
    Sacco JJ; Kenyani J; Butt Z; Carter R; Chew HY; Cheeseman LP; Darling S; Denny M; Urbé S; Clague MJ; Coulson JM
    Oncotarget; 2015 May; 6(15):13757-71. PubMed ID: 25970771
    [TBL] [Abstract][Full Text] [Related]  

  • 9. BAP1/ASXL complex modulation regulates epithelial-mesenchymal transition during trophoblast differentiation and invasion.
    Perez-Garcia V; Lea G; Lopez-Jimenez P; Okkenhaug H; Burton GJ; Moffett A; Turco MY; Hemberger M
    Elife; 2021 Jun; 10():. PubMed ID: 34170818
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comprehensive Pharmacogenomic Profiling of Malignant Pleural Mesothelioma Identifies a Subgroup Sensitive to FGFR Inhibition.
    Quispel-Janssen JM; Badhai J; Schunselaar L; Price S; Brammeld J; Iorio F; Kolluri K; Garnett M; Berns A; Baas P; McDermott U; Neefjes J; Alifrangis C
    Clin Cancer Res; 2018 Jan; 24(1):84-94. PubMed ID: 29061644
    [No Abstract]   [Full Text] [Related]  

  • 11. Mesothelioma patient derived tumor xenografts with defined BAP1 mutations that mimic the molecular characteristics of human malignant mesothelioma.
    Kalra N; Zhang J; Thomas A; Xi L; Cheung M; Talarchek J; Burkett S; Tsokos MG; Chen Y; Raffeld M; Miettinen M; Pastan I; Testa JR; Hassan R
    BMC Cancer; 2015 May; 15():376. PubMed ID: 25952750
    [TBL] [Abstract][Full Text] [Related]  

  • 12.
    Guazzelli A; Meysami P; Bakker E; Demonacos C; Giordano A; Krstic-Demonacos M; Mutti L
    Int J Mol Sci; 2019 Jan; 20(2):. PubMed ID: 30669483
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Monoubiquitination of ASXLs controls the deubiquitinase activity of the tumor suppressor BAP1.
    Daou S; Barbour H; Ahmed O; Masclef L; Baril C; Sen Nkwe N; Tchelougou D; Uriarte M; Bonneil E; Ceccarelli D; Mashtalir N; Tanji M; Masson JY; Thibault P; Sicheri F; Yang H; Carbone M; Therrien M; Affar EB
    Nat Commun; 2018 Oct; 9(1):4385. PubMed ID: 30349006
    [TBL] [Abstract][Full Text] [Related]  

  • 14. BAP1 Is Altered by Copy Number Loss, Mutation, and/or Loss of Protein Expression in More Than 70% of Malignant Peritoneal Mesotheliomas.
    Leblay N; Leprêtre F; Le Stang N; Gautier-Stein A; Villeneuve L; Isaac S; Maillet D; Galateau-Sallé F; Villenet C; Sebda S; Goracci A; Byrnes G; McKay JD; Figeac M; Glehen O; Gilly FN; Foll M; Fernandez-Cuesta L; Brevet M
    J Thorac Oncol; 2017 Apr; 12(4):724-733. PubMed ID: 28034829
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Familial and Somatic
    Peng H; Prokop J; Karar J; Park K; Cao L; Harbour JW; Bowcock AM; Malkowicz SB; Cheung M; Testa JR; Rauscher FJ
    Cancer Res; 2018 Mar; 78(5):1200-1213. PubMed ID: 29284740
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sensitivity of Mesothelioma Cells to PARP Inhibitors Is Not Dependent on BAP1 but Is Enhanced by Temozolomide in Cells With High-Schlafen 11 and Low-O6-methylguanine-DNA Methyltransferase Expression.
    Rathkey D; Khanal M; Murai J; Zhang J; Sengupta M; Jiang Q; Morrow B; Evans CN; Chari R; Fetsch P; Chung HJ; Xi L; Roth M; Filie A; Raffeld M; Thomas A; Pommier Y; Hassan R
    J Thorac Oncol; 2020 May; 15(5):843-859. PubMed ID: 32004714
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tumor-derived neomorphic mutations in ASXL1 impairs the BAP1-ASXL1-FOXK1/K2 transcription network.
    Xia YK; Zeng YR; Zhang ML; Liu P; Liu F; Zhang H; He CX; Sun YP; Zhang JY; Zhang C; Song L; Ding C; Tang YJ; Yang Z; Yang C; Wang P; Guan KL; Xiong Y; Ye D
    Protein Cell; 2021 Jul; 12(7):557-577. PubMed ID: 32683582
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Highly expressed EZH2 in combination with BAP1 and MTAP loss, as detected by immunohistochemistry, is useful for differentiating malignant pleural mesothelioma from reactive mesothelial hyperplasia.
    Yoshimura M; Kinoshita Y; Hamasaki M; Matsumoto S; Hida T; Oda Y; Iwasaki A; Nabeshima K
    Lung Cancer; 2019 Apr; 130():187-193. PubMed ID: 30885343
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A common ancestry for BAP1 and Uch37 regulators.
    Sanchez-Pulido L; Kong L; Ponting CP
    Bioinformatics; 2012 Aug; 28(15):1953-6. PubMed ID: 22645167
    [TBL] [Abstract][Full Text] [Related]  

  • 20. BAP1 facilitates diagnostic objectivity, classification, and prognostication in malignant pleural mesothelioma.
    McGregor SM; Dunning R; Hyjek E; Vigneswaran W; Husain AN; Krausz T
    Hum Pathol; 2015 Nov; 46(11):1670-8. PubMed ID: 26376834
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.